Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Metrics to compare | GYRE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGYREPeersSector | |
---|---|---|---|---|
P/E Ratio | 95.3x | −0.5x | −0.5x | |
PEG Ratio | 1.00 | 0.00 | 0.00 | |
Price / Book | 10.1x | 1.8x | 2.6x | |
Price / LTM Sales | 6.9x | 9.5x | 3.1x | |
Upside (Analyst Target) | 146.0% | 174.0% | 47.6% | |
Fair Value Upside | Unlock | 20.6% | 6.7% | Unlock |